Sapience Therapeutics ST316 Shows 47% Response Rate in Phase 2 Colorectal Cancer Trial

Key Takeaways

• ST316 achieved 47% objective response rate and 93% disease control rate in second-line colorectal cancer patients
• First-in-class β-catenin antagonist targets novel Wnt signaling pathway mechanism in cancer treatment
• Results presented at AACR 2026 position ST316 as potential breakthrough therapy for large unmet medical need

---

Sapience Therapeutics announced breakthrough Phase 2 clinical results for ST316, its first-in-class β-catenin antagonist, showing exceptional efficacy in second-line colorectal cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2026.

The Tarrytown, New York-based clinical-stage biotechnology company reported that ST316 achieved a 47% objective response rate (ORR) with disease control in 93% of patients with second-line colorectal cancer (2L CRC). These results represent some of the most promising efficacy signals seen in this patient population.

Novel Mechanism Targets Wnt Pathway

ST316 represents a first-in-class approach to treating colorectal cancer by antagonizing β-catenin, a key protein in the Wnt signaling pathway. This pathway is frequently dysregulated in colorectal cancer, making it an attractive therapeutic target that has been difficult to drug until now.

“These highly encouraging initial clinical results demonstrate the potential of our peptide therapeutic approach to address oncogenic dysregulation that drives cancer,” the company stated in their announcement.

Significant Market Opportunity

The second-line colorectal cancer market represents a significant unmet medical need, with current standard-of-care options including regorafenib (Stivarga), trifluridine/tipiracil (Lonsurf), and various targeted therapies like cetuximab (Erbitux) and panitumumab (Vectibix). The exceptional response rates seen with ST316 could position it as a preferred treatment option in this setting.

Colorectal cancer is the third most common cancer worldwide, with approximately 150,000 new cases diagnosed annually in the United States alone. Patients who progress after first-line therapy face limited treatment options and poor prognosis, highlighting the critical need for more effective therapies.

Breakthrough Therapy Potential

The strong efficacy signals from ST316 may qualify the drug for FDA Breakthrough Therapy Designation, which could accelerate its development timeline and regulatory review process. This designation is reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions.

Sapience Therapeutics focuses on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that drive cancer. The company’s approach targets previously undruggable pathways using innovative peptide-based therapeutics.

Next Steps and Timeline

While the company has not yet announced specific next steps, the strong Phase 2 data typically would support advancement to Phase 3 registration-enabling trials. The presentation at AACR 2026 also positions Sapience Therapeutics as an attractive partnership or acquisition target for larger pharmaceutical companies seeking to expand their oncology portfolios.

Investors and analysts will be closely watching for additional safety and durability data, as well as the company’s plans for advancing ST316 through late-stage development. The novel mechanism of action and exceptional efficacy results suggest ST316 could become a significant player in the colorectal cancer treatment landscape.

---

Frequently Asked Questions

What does this mean for colorectal cancer patients?

The 47% response rate and 93% disease control rate represent significantly better outcomes than many current second-line treatments, potentially offering new hope for patients whose cancer has progressed after initial therapy.

When will ST316 be available to patients?

ST316 is still in Phase 2 trials and would need to complete Phase 3 studies and gain FDA approval before becoming commercially available, likely several years away depending on development timeline and regulatory review.

How does ST316 compare to existing colorectal cancer treatments?

ST316’s 47% response rate appears superior to many current second-line options, and its novel β-catenin antagonist mechanism offers a first-in-class approach that targets the Wnt pathway, which hasn’t been successfully drugged before in cancer.